ezetimibe has been researched along with Coronary Heart Disease in 113 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 61 (53.98) | 29.6817 |
| 2010's | 47 (41.59) | 24.3611 |
| 2020's | 5 (4.42) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, L; Zhao, S; Zhao, W | 1 |
| Carvajal-Gonzalez, S; Dullea, R; Furtado, JD; Nicholls, SJ; Ruotolo, G; Sacks, FM | 1 |
| Li, B; Li, Y; Liu, YQ; Peng, WZ; Wen, JK; Xu, ZS | 1 |
| Noack, F; Noutsias, M; Rohe, K; Schlitt, A; Treede, H; Waßmuth, S | 1 |
| Han, B; Liu, Y | 1 |
| Baxter, CA; Davies, GM; Vyas, A | 1 |
| Blom, DJ; Cannon, CP; Cariou, B; Chaudhari, U; Colhoun, HM; El Shahawy, M; Lecorps, G; McKenney, JM; Pordy, R | 1 |
| Mikhailidis, DP; Paraskevas, KI | 1 |
| Canullo, L; Casu, G; Cercone, S; Cuccia, C; De Ferrari, GM; Di Biase, M; Gitt, AK; Guasti, L; Horack, M; Lautsch, D; Nicosia, A; Perna, GP; Picco, F; Strazzella, C; Totaro, R | 1 |
| Bennie, M; Do Nascimento, RC; Godman, B; Hurding, S; Kurdi, A; Leporowski, A; MacBride-Stewart, S; Morton, A; Ryan, M | 1 |
| Kuang, H; Li, L; Lu, T; Shou, W; Yi, Q; Zhou, X | 1 |
| Cordero, A; Fácila, L; Galve, E; González Juanatey, JR | 1 |
| Bode, C; Clemens, A; Hehn, P; Hilgendorf, I; Kaier, K; Manhart, L; Merz, J; Peikert, A; Schäfer, I; Sheng, X; Stachon, P; von Zur Mühlen, C; Willecke, F; Wolf, D; Zehender, M; Zirlik, A | 1 |
| Brath, H; Kästenbauer, T; Toplak, H; Wascher, TC | 1 |
| Liu, Y; Mi, SH; Wang, LY; Wang, QH; Wu, WF; Zhang, T | 1 |
| Goldberg, LR; Makkar, KM; Sanoski, CA; Spinler, SA | 1 |
| Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL | 1 |
| Machado Cesar, LA; Mangili, LC; Mangili, OC; Maranhão, RC; Mesquita, CH; Moron Gagliardi, AC; Santos, RD; Schaefer, EJ; Tanaka, A | 1 |
| Barbosa, SP; Bianco, HT; Camargo, LM; Fonseca, FA; França, CN; Izar, MC; Lins, LS; Pinheiro, LF | 1 |
| Huang, W; Qian, H; Sun, L | 1 |
| Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM | 1 |
| Ambegaonkar, B; Davies, G; Ejzykowicz, F; Hsu, TY; Laires, PA | 1 |
| Besseling, J; Kastelein, JJ; Sjouke, B | 1 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Bittner, V; Deng, L; Farkouh, ME; Glasser, SP; Kent, ST; Muntner, P; Rosenson, RS; Taylor, B | 1 |
| Diekmann, J; Farr, M; Horstkotte, D; Mellwig, KP; van Buuren, F | 1 |
| Bays, HE; Chaudhari, U; Jones, PH; Lorenzato, C; Miller, K; Pordy, R; Robinson, JG | 1 |
| Kevelaitiene, S; Slapikas, R | 1 |
| Alemao, E; Davies, GM; Hildebrandt, P; Keiding, H | 1 |
| Desai, A; Resnic, FS | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Spence, JD | 1 |
| Jones, PH | 1 |
| de Lorgeril, M | 1 |
| Costa, JA; González, C; Miralles, A; Pascual, JM; Pérez-Lahiguera, F; Rodilla, E | 1 |
| Blumenthal, RS; Michos, ED | 1 |
| Devine, PJ; Griffen, L; Miller, M; Stanek, EJ; Taylor, AJ; Turco, M; Villines, TC; Weissman, NJ | 2 |
| Bots, ML; Kastelein, JJ | 1 |
| Cheng, SJ; Ma, Q; Xu, FX; Yan, HB | 1 |
| Kole, LA | 1 |
| de Campo, A; März, W; Scharnagl, H; Schmölzer, I; Sourij, H; Stojakovic, T; Wascher, TC | 1 |
| Parhofer, K | 1 |
| Ben-Yehuda, O; Bird, S; Constance, C; Hanson, ME; Jones-Burton, C; Lee, R; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Halcox, JP; Lindsay, AC | 1 |
| Duivenvoorden, R; Kastelein, JJ; Vergeer, M | 1 |
| Roman, MJ | 1 |
| Weiss, SH | 1 |
| Ahmed, MH | 1 |
| Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ | 1 |
| Gensini, GF; Hanson, ME; Le Grazie, C; Rotella, CM; Zaninelli, A | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Tershakovec, AM | 1 |
| Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F | 1 |
| Plans-Rubió, P | 1 |
| Hessen, SE; Karalis, DG; Liu, L; Subramanya, RD; Victor, MF | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M | 1 |
| Enko, K; Hata, Y; Ito, H; Kohno, K; Kubo, M; Kusano, KF; Miyoshi, T; Morita, H; Murakami, M; Nakamura, K; Yunoki, K | 1 |
| Forge, BH | 1 |
| Bae, JW; Choi, CI; Jang, CG; Kim, MJ; Lee, SY; Lee, YH | 1 |
| Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D | 1 |
| Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kugiyama, K; Nakamura, T; Obata, JE; Saito, Y; Watanabe, K; Watanabe, Y | 1 |
| Stanek, EJ; Taylor, AJ; Villines, TC | 1 |
| Chechetkin, AV; Filippov, AE; Kozobova, AI; Popova, NN; Vashchenko, TN; Vashchenko, VI; Vil'ianinov, VN | 1 |
| Bestehorn, K; Gitt, AK; Jannowitz, C; Karmann, B; Pittrow, D; Schaefer, JR; Sonntag, F; Weizel, A | 1 |
| Iino, K; Ishida, M; Ito, H; Kosaka, T; Koyama, T; Nobori, K; Oguma, Y; Terata, Y; Watanabe, H; Yamazaki, D | 1 |
| Császár, A; Márk, L | 1 |
| Sacks, FM | 1 |
| Clearfield, MB | 1 |
| Sudhop, T; von Bergmann, K | 1 |
| Jones, PH; Neal, RC | 1 |
| Krone, W; Müller-Wieland, D | 1 |
| Tellier, P | 1 |
| Davies, S; Evans, M; Rees, A; Roberts, A | 1 |
| Cho, M; Feldman, T; Insull, W; Koren, M; Kush, D; Lewin, A; McKenney, J; Mitchel, Y; Schrott, H; Shah, S; Sidisin, M | 1 |
| Clark, LT | 1 |
| Naoumova, RP; Soutar, AK; Thompson, GR | 1 |
| Kroemer, HK; Meyer Zu Schwabedissen, H | 1 |
| Denke, MA | 1 |
| Charlotte, N; Sani, M | 1 |
| Alemao, E; Cook, JR; Drummond, M; Yin, D | 1 |
| Alemao, E; Badia, X; Cook, JR; Davies, G; Krobot, KJ; Lipka, L; Veltri, E; Yin, D | 1 |
| Coleman, CI; Gillespie, EL; Perkerson, KA | 1 |
| Alemao, E; Cook, JR; Davies, GM; Erbey, J; Veltri, EP | 1 |
| Clader, JW | 1 |
| Alings, AM; Allen, C; Banai, S; Brohet, C; Davies, MJ; Massaad, R | 1 |
| Adgey, J; Allen, C; Bedarida, GV; Cruz-Fernández, JM; Johnson-Levonas, AO; Massaad, R | 1 |
| Allen, C; Davies, MJ; Farnier, M; Massaad, R; Volpe, M | 1 |
| Sármán, B | 1 |
| Ballantyne, CM | 1 |
| Füessl, HS | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Ballantyne, CM; Brady, WE; Davies, MJ; Feldman, TA; McKenney, J; Mitchel, YB; Palmisano, J; Shah, A | 1 |
| Davies, MJ; Maccubbin, D; Mitchel, Y; Ose, L; Rotonda, J; Shah, A; Tribble, D; Veltri, E | 1 |
| Hughes, EA; Patel, JV | 1 |
| Katz, U; Shoenfeld, Y; Szyper-Kravitz, M; Zimlichman, E | 1 |
| Shechter, M | 1 |
| Abinader, EG | 1 |
| Blagden, MD; Chipperfield, R | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Dagli, N; Karaca, I; Yavuzkir, M | 1 |
| Bays, HE; Neff, D; Tershakovec, AM; Tomassini, JE | 1 |
| Böhm, F; Pernow, J; Rydén, L; Settergren, M | 1 |
| Brown, WV | 1 |
| Yamashita, S | 1 |
| Miettinen, TA | 1 |
| Leitersdorf, E | 1 |
25 review(s) available for ezetimibe and Coronary Heart Disease
| Article | Year |
|---|---|
Virtual screening for cholesterol absorption inhibitors.
Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Transport; Cholesterol; Coronary Disease; Ezetimibe; Gene Expression; High-Throughput Screening Assays; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Membrane Proteins; Membrane Transport Proteins; Structure-Activity Relationship; User-Computer Interface | 2014 |
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.
Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL | 2014 |
Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014).
Topics: Anticholesteremic Agents; Apolipoproteins B; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Cost-Benefit Analysis; Ezetimibe; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Mass Screening; Mutation; Netherlands; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; Risk; Serine Endopeptidases | 2015 |
[A new approach to the treatment of dyslipidemia].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors | 2008 |
Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome | 2010 |
[Lipid therapy in daily routine].
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Female; General Practice; Germany; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Prospective Studies; Simvastatin | 2012 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
Lipid-lowering: can ezetimibe help close the treatment gap?
Topics: Anticholesteremic Agents; Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Lipoproteins, LDL; Risk | 2003 |
[Hyperlipidemia: therapeutic principles in clinical practice].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Insulin Resistance; Nutritional Physiological Phenomena; Practice Guidelines as Topic; Risk Factors; Time Factors; Weight Loss | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Topics: Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Ezetimibe; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2004 |
Optimizing lipid lowering in patients at risk.
Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Risk Assessment | 2004 |
Current management of severe homozygous hypercholesterolaemias.
Topics: Adolescent; Adult; Apolipoproteins B; Azetidines; Blood Component Removal; Child; Cholesterol; Coronary Disease; Ezetimibe; Female; Genes, Recessive; Genetic Therapy; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Liver Transplantation; Male; Models, Genetic; Mutation; Pregnancy; Time Factors | 2004 |
[Ezetimib].
Topics: Anticholesteremic Agents; Arteriosclerosis; Azetidines; Coronary Disease; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemias | 2004 |
Coadministration of multidrug therapy to achieve lipid goals.
Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Risk Factors | 2004 |
Ezetimibe and other azetidinone cholesterol absorption inhibitors.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Intestinal Absorption; Structure-Activity Relationship | 2005 |
[New results in the management of hypercholesterolemia].
Topics: Anticholesteremic Agents; Azetidines; C-Reactive Protein; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Enzyme Inhibitors; Evidence-Based Medicine; Ezetimibe; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Practice Guidelines as Topic; Sterol O-Acyltransferase | 2005 |
Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Risk Factors | 2005 |
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Treatment Outcome | 2006 |
Ezetimibe: cholesterol lowering and beyond.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Controlled Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia | 2008 |
Novel approaches to lipid lowering: what is on the horizon?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Evaluation; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Prognosis | 2001 |
[Other antihyperlipidemic drugs with novel mechanism].
Topics: Animals; Arteriosclerosis; Azetidines; Benzylamines; Carrier Proteins; CCAAT-Enhancer-Binding Proteins; Chenodeoxycholic Acid; Cholesterol; Coronary Disease; Diphosphonates; DNA-Binding Proteins; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lithocholic Acid; Organic Anion Transporters, Sodium-Dependent; Oxygenases; Squalene Monooxygenase; Sterol Regulatory Element Binding Protein 1; Symporters; Thiophenes; Transcription Factors | 2001 |
Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Ezetimibe; Humans; Hypercholesterolemia | 2001 |
Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Europe; Ezetimibe; Humans; Hypercholesterolemia; Practice Guidelines as Topic | 2002 |
30 trial(s) available for ezetimibe and Coronary Heart Disease
| Article | Year |
|---|---|
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein C-III; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Coronary Disease; Ezetimibe; Female; Heart Disease Risk Factors; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged | 2022 |
Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Clinical Decision-Making; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections, Subcutaneous; Male; Medication Adherence; Middle Aged; Time Factors; Treatment Outcome | 2017 |
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome | 2014 |
Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects.
Topics: Aged; Azetidines; Cholesterol Esters; Chylomicron Remnants; Chylomicrons; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Kinetics; Male; Middle Aged; Simvastatin; Triglycerides; Triolein | 2014 |
Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy.
Topics: Aged; Anticholesteremic Agents; Aspirin; Azetidines; Cell-Derived Microparticles; Cholesterol, LDL; Clopidogrel; Coronary Disease; Drug Combinations; Endothelial Progenitor Cells; Ezetimibe; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Simvastatin; Ticlopidine; Triglycerides | 2014 |
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Extended-release niacin or ezetimibe and carotid intima-media thickness.
Topics: Aged; Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Niacin; Risk Factors; Single-Blind Method; Triglycerides; Tunica Intima; Tunica Media; Ultrasonography | 2009 |
Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies | 2010 |
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2010 |
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Niacin; Single-Blind Method; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography | 2010 |
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Risk Factors; Simvastatin; Statistics as Topic | 2010 |
Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.
Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Racial Groups; Risk Factors; Sex Factors; Treatment Outcome; Young Adult | 2011 |
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2010 |
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.
Topics: Aged; Apolipoproteins B; Azetidines; Cholesterol; Coronary Disease; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Impact of hypertriglyceridemia on endothelial dysfunction during statin ± ezetimibe therapy in patients with coronary heart disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Azetidines; Cholesterol, HDL; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Japan; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Regression Analysis; Secondary Prevention; Triglycerides; Vasodilation | 2011 |
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glucose Intolerance; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Oxidation-Reduction; Prospective Studies; Pyrroles | 2012 |
A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipoproteinemias; Lipoproteins; Male; Middle Aged; Triglycerides; Vasodilation | 2012 |
Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Ezetimibe; Female; Humans; Male; Risk Factors | 2012 |
Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Serum Amyloid P-Component; Sulfonamides; Tumor Necrosis Factor-alpha | 2013 |
Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Risk Factors; Simvastatin; Treatment Outcome | 2004 |
LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Simvastatin; Treatment Outcome | 2005 |
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Safety | 2005 |
Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
Topics: Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; International Cooperation; Male; Middle Aged; Prospective Studies; Safety; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2005 |
Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Treatment Outcome | 2006 |
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2007 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
Topics: Administration, Oral; Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; C-Reactive Protein; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Brachial Artery; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation Mediators; Lipids; Male; Middle Aged; Plethysmography; Regional Blood Flow; Simvastatin; Vasodilation | 2008 |
58 other study(ies) available for ezetimibe and Coronary Heart Disease
| Article | Year |
|---|---|
The clinical effect of Xuezhikang combined with ezetimibe in the treatment of coronary heart disease in lipid-lowering treatment and its influence on blood lipid level.
Topics: Coronary Disease; Drug Therapy, Combination; Drugs, Chinese Herbal; Ezetimibe; Humans; Lipids | 2023 |
Effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease: a retrospective analysis.
Topics: C-Reactive Protein; Cholesterol, HDL; Coronary Disease; Ezetimibe; Humans; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2023 |
Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; Coronary Disease; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipids; Male; Medication Adherence; Middle Aged; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Retrospective Studies; Rosuvastatin Calcium; Treatment Outcome | 2022 |
Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Fees, Pharmaceutical; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Stroke; United States | 2017 |
More on carotid atherosclerosis and ezetimibe.
Topics: Atorvastatin; Carotid Artery Diseases; Carotid Stenosis; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans | 2017 |
Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Clinical Decision-Making; Coronary Disease; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Middle Aged; Patient Selection; PCSK9 Inhibitors; Registries; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2018 |
Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications.
Topics: Anticholesteremic Agents; Coronary Disease; Dose-Response Relationship, Drug; Drug Costs; Drugs, Generic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inappropriate Prescribing; National Health Programs; Practice Patterns, Physicians'; Scotland | 2018 |
Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report.
Topics: Adolescent; Anticholesteremic Agents; Aspirin; Coronary Disease; Ezetimibe; Female; Heart Failure; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mutation; Myocardial Ischemia; Platelet Aggregation Inhibitors; Receptors, LDL; Xanthogranuloma, Juvenile | 2018 |
Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors.
Topics: Anticholesteremic Agents; Apoptosis; Cholesterol, LDL; Coronary Disease; Ezetimibe; Humans; Incidence; PCSK9 Inhibitors; Spain | 2019 |
Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort.
Topics: Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cross-Sectional Studies; Ezetimibe; Female; Humans; Incidence; Inflammation; Male; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies | 2020 |
[Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
Topics: Ambulatory Care; Anticholesteremic Agents; Austria; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Utilization; Ezetimibe; Fibric Acids; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mass Screening; Risk Factors; Treatment Outcome; Triglycerides | 2012 |
Change in cholesterol absorption and synthesis markers in patients with coronary heart disease after combination therapy with simvastatin plus ezetimibe.
Topics: Adult; Aged; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin | 2013 |
An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors.
Topics: Adult; Aged; Allografts; Anticholesteremic Agents; Azetidines; Calcineurin Inhibitors; Cholesterol, LDL; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Hospital Bed Capacity, 500 and over; Hospitals, Teaching; Humans; Immunosuppressive Agents; Male; Medical Records; Middle Aged; Retrospective Studies | 2013 |
Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Lipids; Male; Middle Aged; Portugal; Quality-Adjusted Life Years; Risk Factors; Rosuvastatin Calcium; Smoking | 2015 |
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
Topics: Adult; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Medicare; Niacin; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; United States | 2015 |
[Homozygous hypercholesterolemia - new therapeutic options in cases with complete lack of LDL- receptor].
Topics: Adult; Anticholesteremic Agents; Benzimidazoles; Blood Component Removal; Codon, Terminator; Combined Modality Therapy; Coronary Disease; DNA Mutational Analysis; Ezetimibe; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Myocardial Revascularization; Receptors, LDL; Simvastatin | 2016 |
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Back Pain; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Influenza, Human; Middle Aged; Myocardial Infarction; Nasopharyngitis; Pruritus; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Stroke; Urinary Tract Infections | 2016 |
[Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Decision Making; Drug Costs; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
[Stable coronary heart disease--lessons from the COURAGE Study. With intensive drug therapy on the success track].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Combined Modality Therapy; Coronary Disease; Coronary Stenosis; Death, Sudden, Cardiac; Ezetimibe; Humans; Kaplan-Meier Estimate; Life Style; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Highlights from the 57th annual scientific session of the American College of Cardiology.
Topics: Aortic Valve; Azetidines; Cardiac Catheterization; Catheter Ablation; Coronary Disease; Drug-Eluting Stents; Ezetimibe; Heart Failure; Heart Valve Diseases; Humans; Mitral Valve Insufficiency; Simvastatin; Surgical Instruments | 2008 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Is carotid intima-media thickness a reliable clinical predictor?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Carotid Artery Diseases; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Achieving cholesterol goals. Current and future drug therapies.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin | 2003 |
[LDL-cholesterol goals and changes in C reactive protein in high coronary risk patients].
Topics: Aged; Azetidines; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Ezetimibe; Female; Humans; Longitudinal Studies; Male; Retrospective Studies; Risk Factors | 2009 |
The HALTS trial--halting atherosclerosis or halted too early?
Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Research Design; Tunica Intima; Tunica Media | 2009 |
Statin therapy with ezetimibe or niacin in high-risk patients.
Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Research Design; Tunica Intima; Tunica Media | 2009 |
[Effectiveness of ezetimibe in improving lipid goal attainment in patients with coronary heart diseases treated with statin].
Topics: Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Creatine Kinase; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Treatment Outcome; Triglycerides | 2009 |
Lipid disorders.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Vitamin B Complex | 2009 |
[Statin plus niacin or ezetimibe? What combination for which patients?].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hypolipidemic Agents; Niacin; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Time Factors | 2009 |
Niacin compared with ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Blood Pressure; Carotid Arteries; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Vasodilator Agents | 2010 |
Niacin compared with ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Tunica Intima; Tunica Media | 2010 |
Niacin compared with ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Carotid Arteries; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Tunica Intima; Tunica Media | 2010 |
Niacin compared with ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Blood Glucose; Carotid Arteries; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Humans; Niacin; Patient Dropouts; Research Design | 2010 |
I have had trouble controlling my cholesterol with a statin alone. Should I consider prescription niacin?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Niacin | 2010 |
Ezetimibe and recent clinical trials: a look on the bright side.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Niacin; Placebos; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides | 2010 |
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
Topics: Azetidines; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Drugs, Generic; Ezetimibe; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Spain; Time Factors | 2010 |
Achieving optimal lipid goals in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Logistic Models; Male; Practice Patterns, Physicians'; Sex Factors; Triglycerides | 2011 |
Managing residual risk in patients receiving statin therapy. Comment.
Topics: Anticholesteremic Agents; Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2011 |
Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults.
Topics: Adult; Aged; Asian People; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Combinations; Drug Synergism; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
[The influence of ezetimibe and simvaststin on platelet aggregation and protein c system in patients with coronary heart disease and hypercholesterolemia].
Topics: Anticholesteremic Agents; Azetidines; Coronary Disease; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Protein C; Simvastatin | 2012 |
Low-density lipoprotein lowering therapy: an analysis of the options.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscular Diseases; Simvastatin | 2002 |
[Ezetimib plus statin combination. A strong duo].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin | 2002 |
A novel therapeutic approach to dyslipidemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Safety | 2003 |
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors | 2003 |
[Even at LDL cholesterol 100mg/dl. "Every coronary disease patient has to receive a statin"].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Humans; Primary Prevention; Risk Factors; Simvastatin | 2003 |
[New combination therapy. Up to 60% lower LDL cholesterol level].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Combinations; Drug Synergism; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2004 |
Lipid-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Risk Factors; Treatment Outcome | 2004 |
Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Coronary Disease; Cost Control; Cost-Benefit Analysis; Disease Progression; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Models, Economic; Reproducibility of Results; Time Factors | 2004 |
Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.
Topics: Anticholesteremic Agents; Azetidines; Coronary Disease; Cost-Benefit Analysis; Decision Support Techniques; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Ezetimibe; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Norway; Risk Factors; Spain | 2004 |
Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl CoA Reductases | 2005 |
Projected coronary heart disease risk benefit with ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Placebos; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2005 |
[MMW- Drug Prize 2005 for simvastatin/ezetimib (Inegy). LDL goal values are easier to reach now].
Topics: Aged; Anticholesteremic Agents; Awards and Prizes; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Combinations; Ezetimibe; Female; Germany; Humans; Male; Periodicals as Topic; Risk Factors; Simvastatin | 2005 |
Intensive lipid-lowering therapy: obvious benefits, possible risks.
Topics: Aged, 80 and over; Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases | 2006 |
Lipid-lowering therapy--benefits and risks.
Topics: Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Risk Factors | 2007 |
Lipid-lowering therapy--benefits and risks.
Topics: Aged, 80 and over; Azetidines; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Risk Factors | 2007 |
[LDL cholesterol in cardiovascular risk patients should be as low as possible].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2007 |